Plus Therapeutics
Price & Volume
Stats
See more52W Range | $0.24-$2.67 |
Market Cap | $8.4M |
Shares Short | 59,847 |
Financials
See moreRevenue (12 Mos) | $5.7M |
Revenue Growth (YoY) | 17.4% |
Gross Profit (12 Mos) | -$5.4M |
Diluted EPS | -$2.37 |
News
See moreYahoo Finance • 18 hours ago
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer
Yahoo Finance • yesterday
Plus Therapeutics Announces New Employment Inducement Grants
Yahoo Finance • 2 days ago
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
Yahoo Finance • 9 days ago
Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases
About
CEO | Dr. Marc H. Hedrick M.B.A., M.D. |
CFO | Mr. Andrew J. Sims CPA |
Address | 4200 Marathon Boulevard, Austin, TX, United States, 78756 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 20 |
